Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician

Small Animal Internal Medicine

Category: Research Abstract - ePoster

(IM04) Comparison of Prednisolone Alone and Prednisolone Combined with Adjunctive Immunosuppressants for Dogs with Immune-mediated Polyarthritis

Friday, June 16, 2023
12:30 PM - 12:45 PM ET
Location: Solutions Center Poster Park - Kiosk 1
ePoster

    Research Abstract – ePoster Presenter(s)

  • JUNGIL KIM, DVM (he/him/his)

    student
    Chungnam National University Veterinary Medical Teaching Hospital / internal medicine
    Deajeon, Taejon-jikhalsi, Republic of Korea

Abstract:

Background: Prednisolone (PDS) is commonly used for primary immune-mediated polyarthritis (IMPA). The comparison of PDS monotherapy and PDS combined with adjunctive immunosuppressant for dogs with IMPA is scarce.

Hypothesis/

Objectives: PDS combined with adjunctive immunosuppression is not superior to PDS alone in terms of efficacy and safety in dogs with IMPA.

Animals: Thirteen client-owned dogs with primary IMPA. 6 dogs (group A) were treated with PDS alone, and 7 dogs (group B) were treated with PDS combined with the additional immunosuppressant.

Methods: Retrospective study. The data collected from the medical records included information regarding signalment, treatment response, and adverse effects.

Results: Complete response (CR) was achieved in both groups. The median time to CR was 19 days (range, 3 to 40) in group A and 17 days (range, 6 to 28) in group B. The median time of initial PDS tapering was 27.5 days (range, 18 to 41) in group A and 35 days (range, 11 to 84) in group B. The relapse was observed in 1 dog in group A and 3 dogs in group B. Adverse effects (AEs) were observed in 2 dogs (PDS-related AEs) in group A and 3 dogs (sporadic infection, n=2; PDS-related AEs, n=3) in group B.

Conclusions and clinical relevance: The efficacy of PDS monotherapy is comparable to PDS combined with adjunctive immunosuppression in dogs with IMPA. Sporadic infections more frequently occurred in the dogs treated with the additional immunosuppressant. The overall findings help us extend our understanding of the treatment for IMPA.